The solute carrier family 18 member A2 (SLC18A2), also known as vesicular monoamine transporter 2 (VMAT2), is a transmembrane protein responsible for transporting monoamine neurotransmitters (e.g., dopamine, serotonin, norepinephrine, and histamine) into synaptic vesicles for storage and regulated release. SLC18A2 antibodies are essential tools for studying the expression, localization, and function of this transporter in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to visualize SLC18A2 distribution in brain regions, endocrine cells, and other tissues. Research involving SLC18A2 antibodies has contributed to understanding neuropsychiatric disorders (e.g., Parkinson’s disease, schizophrenia, and depression) and metabolic conditions linked to monoaminergic dysregulation. Specific antibody clones are validated for selectivity against SLC18A2 isoforms and cross-reactivity checks with related transporters (e.g., SLC18A1/VMAT1). Studies also employ these antibodies to explore pharmacological interactions, such as the effects of VMAT2 inhibitors (e.g., reserpine, tetrabenazine) used in hyperkinetic movement disorders. By enabling precise detection of SLC18A2. these reagents support advances in neuroscience, drug development, and biomarker discovery.